CAH Cardinal Health Inc

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

v3.23.3

Cover Page - shares	3 Months Ended
	Sep. 30, 2023	Oct. 31, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	1-11373
Entity Registrant Name	Cardinal Health, Inc.
Entity Central Index Key	0000721371
Current Fiscal Year End Date	--06-30
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Incorporation, State or Country Code	OH
Entity Tax Identification Number	31-0958666
Entity Address, Address Line One	7000 Cardinal Place
Entity Address, City or Town	Dublin
Entity Address, State or Province	OH
Entity Address, Postal Zip Code	43017
City Area Code	614
Local Phone Number	757-5000
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Title of 12(b) Security	Common shares (without par value)
Trading Symbol	CAH
Security Exchange Name	NYSE
Entity Common Stock, Shares Outstanding		246,468,133

v3.23.3

Condensed Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Revenue	$ 54,763	$ 49,603
Cost of Goods and Services Sold	52,995	47,989
Gross margin	1,768	1,614
Operating expenses:
Distribution, selling, general and administrative expenses	1,197	1,197
Restructuring and employee severance	25	29
Amortization and other acquisition-related costs	64	71
Impairments and (gain)/loss on disposal of assets, net	537	153
Litigation (recoveries)/charges, net	(41)	27
Operating earnings/(loss)	(14)	137
Other (income)/expense, net	(2)	2
Interest expense, net	14	25
Earnings/(loss) before income taxes	(26)	110
Benefit from income taxes	(32)	(1)
Net earnings	6	111
Less: Net earnings attributable to noncontrolling interests	(1)	(1)
Net earnings attributable to Cardinal Health, Inc.	$ 5	$ 110
Earnings per common share attributable to Cardinal Health, Inc.:
Basic (in shares)	$ 0.02	$ 0.41
Diluted (in shares)	$ 0.02	$ 0.40
Weighted-average number of common shares outstanding:
Basic (in shares)	249	271
Diluted (in shares)	250	273
Cash dividends declared per common share	$ 0.5006	$ 0.4957

v3.23.3

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Statement of Comprehensive Income [Abstract]
Net earnings/(loss)	$ 6	$ 111
Other comprehensive loss:
Foreign currency translation adjustments and other	(11)	(58)
Net unrealized gain/(loss) on derivative instruments, net of tax	(3)	(4)
Total other comprehensive loss, net of tax	(14)	(62)
Total comprehensive income/(loss)	(8)	49
Less: comprehensive income attributable to noncontrolling interests	(1)	(1)
Total comprehensive income attributable to Cardinal Health, Inc.	$ (9)	$ 48

v3.23.3

Condensed Consolidated Balance Sheets - USD ($) shares in Thousands, $ in Millions	Sep. 30, 2023	Jun. 30, 2023
Current assets:
Cash and equivalents	$ 3,854	$ 4,043
Trade receivables, net	11,265	11,344
Inventories, net	16,987	15,940
Prepaid expenses and other	2,582	2,362
Assets held for sale	0	144
Total current assets	34,688	33,833
Property and equipment, net	2,441	2,462
Goodwill and other intangibles, net	5,432	6,081
Other Assets	1,149	1,041
Total assets	43,710	43,417
Current liabilities:
Accounts Payable, Current	31,540	29,813
Current portion of long-term obligations and other short-term borrowings	788	792
Other accrued liabilities	2,737	3,059
Liabilities related to assets held for sale	0	42
Total current liabilities	35,065	33,706
Long-term obligations, less current portion	3,890	3,909
Deferred income taxes and other liabilities	$ 8,245	$ 8,653
Preferred shares, without par value:
Preferred Stock, Shares Authorized	500	500
Preferred Stock, Shares Issued	0	0
Preferred Stock, Value, Issued	$ 0	$ 0
Common shares, without par value:
Common Stock, Shares Authorized	755,000	755,000
Common Stock, Shares, Issued	327,000	327,000
Common Stock, Value, Issued	$ 2,728	$ 2,747
Accumulated deficit	(654)	(534)
Treasury Stock, Value	$ (5,400)	$ (4,914)
Treasury Stock, Shares	80,000	76,000
Accumulated other comprehensive loss	$ (165)	$ (151)
Total Cardinal Health, Inc. shareholders' deficit	(3,491)	(2,852)
Noncontrolling interests	1	1
Total shareholders' equity	(3,490)	(2,851)
Total liabilities and shareholders’ deficit	$ 43,710	$ 43,417

v3.23.3

Condensed Consolidated Statement of Shareholders' Equity - USD ($) shares in Thousands, $ in Millions	Total	Common Shares	Accumulated Deficit	Treasury Shares	Accumulated Other Comprehensive Loss	Noncontrolling Interests
Balance at beginning of period (in shares) at Jun. 30, 2022		327,000
Balance at beginning of period at Jun. 30, 2022	$ (706)	$ 2,813	$ (280)		$ (114)	$ 3
Treasury, balance at beginning of period (in shares) at Jun. 30, 2022				(54,000)
Treasury, balance at beginning of period at Jun. 30, 2022				$ (3,128)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	110
Net earnings	111					1
Other comprehensive loss, net of tax	(62)				(62)
Purchase of noncontrolling interests	(2)					(2)
Employee stock plans activity, net of shares withheld for employee taxes (in shares)		0		1,000
Employee stock plans activity, net of shares withheld for employee taxes	11	$ (37)		$ 48
Purchase of treasury shares	(1,000)	$ (200)
Share repurchase program activity (in shares)				(12,000)
Share repurchase program activity	(1,000)			$ (800)
Dividends	(131)		(131)
Other	(1)					(1)
Balance at end of period (in shares) at Sep. 30, 2022		327,000
Balance at end of period at Sep. 30, 2022	$ (1,780)	$ 2,576	(301)		(176)	1
Treasury, balance at end of period (in shares) at Sep. 30, 2022				(65,000)
Treasury, balance at end of period at Sep. 30, 2022				$ (3,880)
Balance at beginning of period (in shares) at Jun. 30, 2023	327,000	327,000
Balance at beginning of period at Jun. 30, 2023	$ (2,851)	$ 2,747	(534)		(151)	1
Treasury, balance at beginning of period (in shares) at Jun. 30, 2023	(76,000)			(76,000)
Treasury, balance at beginning of period at Jun. 30, 2023	$ (4,914)			$ (4,914)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	5
Net earnings	6					1
Other comprehensive loss, net of tax	(14)				(14)
Employee stock plans activity, net of shares withheld for employee taxes (in shares)		0		1,000
Employee stock plans activity, net of shares withheld for employee taxes	0	$ (19)		$ 19
Purchase of treasury shares	(500)
Share repurchase program activity (in shares)				(5,000)
Share repurchase program activity	(505)			$ (505)
Dividends	(125)		(125)
Other	$ (1)					(1)
Balance at end of period (in shares) at Sep. 30, 2023	327,000	327,000
Balance at end of period at Sep. 30, 2023	$ (3,490)	$ 2,728	$ (654)		$ (165)	$ 1
Treasury, balance at end of period (in shares) at Sep. 30, 2023	(80,000)			(80,000)
Treasury, balance at end of period at Sep. 30, 2023	$ (5,400)			$ (5,400)

v3.23.3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities:
Net earnings/(loss)	$ 6	$ 111
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization	172	171
Impairments and (gain)/loss on disposal of assets, net	537	153
Share-based compensation	29	23
Provision for bad debts	29	29
Change in operating assets and liabilities, net of effects from acquisitions and divestitures:
(Increase)/decrease in trade receivables	50	(508)
Increase in inventories	(1,057)	(264)
Increase in accounts payable	1,727	1,234
Other accrued liabilities and operating items, net	(948)	(926)
Net cash provided by operating activities	545	23
Cash flows from investing activities:
Additions to property and equipment	(92)	(70)
Proceeds from disposal of property and equipment	1	2
Purchases of investments	1	3
Proceeds from investments	1	1
Proceeds from Hedge, Investing Activities	28	0
Net cash used in investing activities	(63)	(70)
Cash flows from financing activities:
Reduction of long-term obligations	(7)	(7)
Net tax withholdings from share-based compensation	(28)	(14)
Dividends on common shares	(131)	(142)
Purchase of treasury shares	(500)	(1,000)
Net cash used in financing activities	(666)	(1,163)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations	(5)	(15)
Net decrease in cash and equivalents	(189)	(1,225)
Cash and equivalents at beginning of period	4,043	4,717
Cash and equivalents at end of period	$ 3,854	$ 3,492

v3.23.3

Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	1. Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively. References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (this "Form 10-Q") are to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise. Our fiscal year ends on June 30. References to fiscal 2024 and 2023 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2024 and June 30, 2023, respectively. Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. In addition, financial results presented for this fiscal 2024 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2024. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2023 (the "2023 Form 10-K"). Recently Issued Financial Accounting Standards Not Yet Adopted We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2023 Form 10-K. There were no accounting standards issued in fiscal 2024 that will have a material impact on our condensed consolidated financial statements. Recently Adopted Financial Accounting Standards There were no new material accounting standards adopted in the three months ended September 30, 2023.

v3.23.3

Divestitures	3 Months Ended
	Sep. 30, 2023
Discontinued Operations and Disposal Groups [Abstract]
Disposal Groups, Including Discontinued Operations, Disclosure	2. Divestitures On June 5, 2023, we signed a definitive agreement to contribute the Outcomes™ business to Transaction Data Systems ("TDS"), a portfolio company of BlackRock Long Term Private Capital and GTCR, in exchange for a 16 percent equity interest in the combined entity. The transaction closed on July 10, 2023 and we recognized a pre-tax gain of $53 million during the three months ended September 30, 2023, which was included in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings. This gain includes our initial recognition of an equity method investment in the combined entity for $147 million. We determined that the divestiture of the Outcomes™ business does not meet the criteria to be classified as discontinued operations. The Outcomes™ business operated within our Pharmaceutical segment.

v3.23.3

Restructuring and Employee Severance	3 Months Ended
	Sep. 30, 2023
Restructuring Charges [Abstract]
Restructuring and Employee Severance	3. Restructuring and Employee Severance The following table summarizes restructuring and employee severance costs: Three Months Ended September 30, (in millions) 2023 2022 Employee-related costs $ 7  $ 19  Facility exit and other costs 18  10  Total restructuring and employee severance $ 25  $ 29  Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of project consulting fees, accelerated depreciation, professional, project management and other service fees to support divestitures, costs associated with vacant facilities and certain other divestiture-related costs. During the three months ended September 30, 2023, restructuring and employee severance costs were primarily related to certain projects resulting from reviews of our strategy, portfolio, capital-allocation framework and operations and the implementation of certain enterprise-wide cost-savings measures. During the three months ended September 30, 2022, restructuring and employee severance costs were primarily related to the implementation of certain enterprise-wide cost-savings measures. The following table summarizes activity related to liabilities associated with restructuring and employee severance: (in millions) Employee- Related Costs Facility Exit and Other Costs Total Balance at June 30, 2023 $ 44  $ 2  $ 46  Additions 6  4  10  Payments and other adjustments (15) (2) (17) Balance at September 30, 2023 $ 35  $ 4  $ 39

v3.23.3

Goodwill and Other Intangible Assets	3 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure	4. Goodwill and Other Intangible Assets Goodwill The following table summarizes the changes in the carrying amount of goodwill by segment and in total: (in millions) Pharmaceutical Medical (1) Total Balance at June 30, 2023 $ 2,649  $ 1,960  $ 4,609  Foreign currency translation adjustments and other —  (3) (3) Goodwill impairment —  (581) (581) Balance at September 30, 2023 $ 2,649  $ 1,376  $ 4,025  (1)At September 30, 2023 and June 30, 2023, the Medical segment accumulated goodwill impairment loss was $5.3 billion and $4.7 billion, respectively. Due to an increase in the risk-free interest rate used in the discount rate, we elected to bypass the qualitative assessment and perform quantitative goodwill impairment testing for the Medical operating segment (excluding our Cardinal Health at-Home Solutions division) (“Medical Unit”) at September 30, 2023. Our determination of the estimated fair value of the Medical Unit is based on a combination of the income-based approach (using a discount rate of 11 percent and a terminal growth rate of 2 percent), and market-based approaches. Additionally, we assigned a weighting of 80 percent to the discounted cash flow method, 10 percent to the guideline public company method, and 10 percent to the guideline transaction method. The carrying amount exceeded the fair value, which resulted in a pre-tax impairment charge of $581 million for the Medical Unit, which was recognized during the three months ended September 30, 2023 and is included in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings. This impairment charge was driven by an increase of 1 percent in the discount rate primarily due to an increase in the risk-free interest rate. The discount rate used for the interim goodwill impairment testing at June 30, 2023 was 10 percent. The carrying value of the Medical Unit at September 30, 2023 after recognizing the impairment charge was $5.3 billion, of which $141 million was goodwill. During the three months ended September 30, 2022, we performed interim quantitative goodwill impairment testing for the Medical Unit. This quantitative testing resulted in the carrying amount of the Medical Unit exceeding the fair value, resulting in a pre-tax impairment charge of $154 million. Other Intangible Assets The following tables summarize other intangible assets by class at: September 30, 2023 (in millions) Gross Intangible Accumulated Amortization Net Intangible Weighted- Average Remaining Amortization Period (Years) Indefinite-life intangibles: Trademarks and patents $ 12  $ —  $ 12  N/A Total indefinite-life intangibles 12  —  12  N/A Definite-life intangibles: Customer relationships 3,164  2,307  857  9 Trademarks, trade names and patents 546  387  159  8 Developed technology and other 1,021  642  379  8 Total definite-life intangibles 4,731  3,336  1,395  9 Total other intangible assets $ 4,743  $ 3,336  $ 1,407  N/A June 30, 2023 (in millions) Gross Intangible Accumulated Amortization Net Intangible Indefinite-life intangibles: Trademarks and patents $ 11  $ —  $ 11  Total indefinite-life intangibles 11  —  11  Definite-life intangibles: Customer relationships 3,174  2,274  900  Trademarks, trade names and patents 546  380  166  Developed technology and other 1,021  626  395  Total definite-life intangibles 4,741  3,280  1,461  Total other intangible assets $ 4,752  $ 3,280  $ 1,472  Total amortization of intangible assets was $64 million and $71 million for the three months ended September 30, 2023 and 2022, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2024 through 2028 is as follows: $190 million, $228 million, $205 million, $173 million and $146 million.

v3.23.3

Long-Term Obligations and Other Short-Term Borrowings	3 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Long-Term Obligations and Other Short-Term Borrowings	5. Long-Term Obligations and Other Short-Term Borrowings Long-Term Debt We had total long-term obligations, including the current portion and other short-term borrowings, of $4.7 billion at both September 30, 2023 and June 30, 2023. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $31.5 billion and $29.8 billion at September 30, 2023 and June 30, 2023, respectively. Other Financing Arrangements In addition to cash and equivalents and operating cash flow, other sources of liquidity include a $2.0 billion commercial paper program backed by a $2.0 billion revolving credit facility. We also have a $1.0 billion committed receivables sales facility. At September 30, 2023, we had no amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility. In February 2023, we extended our $2.0 billion revolving credit facility through February 25, 2028. In September 2022, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (“CHF”) through September 30, 2025. In September 2023, Cardinal Health 23 Funding, LLC ("CH-23 Funding") was added as a seller under our committed receivables sales facility. Each of CHF and CH-23 Funding was organized for the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, each of CHF and CH-23 Funding is a separate legal entity from Cardinal Health, Inc. and from our respective subsidiary that sells receivables to CHF or CH-23 Funding, as applicable. Each of CHF and CH-23 Funding is designed to be a special purpose, bankruptcy-remote entity whose respective assets are available solely to satisfy the claims of its respective creditors. Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. As of September 30, 2023, we were in compliance with this financial covenant.

v3.23.3

Commitments, Contingent Liabilities and Litigation	3 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments, Contingent Liabilities and Litigation	6. Commitments, Contingent Liabilities and Litigation Commitments Generic Sourcing Venture with CVS Health In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health Corporation ("CVS Health") for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement. Contingencies New York Opioid Stewardship Act In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $100 million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017. Subsequently, New York passed a new statute that modified the assessment going forward and limited the OSA to two years (2017 and 2018). We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. During the fiscal year 2023, we recorded $6 million of income to reduce the previously estimated accrual to the invoiced amount for the calendar year 2018 assessment. At June 30, 2023, we had an outstanding liability of $3 million, which was paid in full during first quarter of fiscal year 2024. Legal Proceedings We become involved from time to time in disputes, litigation and regulatory matters. From time to time, we determine that products we distribute, source, manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, restrictions on importation, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits. From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions. We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government. We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates. We recognize income from the favorable outcome of litigation when we receive the associated cash or assets. We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges, net, in our condensed consolidated statements of earnings; however, losses and recoveries of lost profits from disputes that occur in the ordinary course of business are included within segment profit. Opioid Lawsuits and Investigations Cardinal Health, other pharmaceutical wholesalers and other participants in the pharmaceutical supply chain have been named as a defendant in lawsuits related to the distribution of opioid pain medications. These lawsuits seek equitable relief and monetary damages based on a variety of legal theories, including various common law claims, such as public nuisance, negligence, unjust enrichment, personal injury, as well as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organizations Act and various other statutes. Plaintiffs in these lawsuits include governmental entities, as well as private parties, such as unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals. We have also received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information, subpoenas and other requests from other DOJ offices. These investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures and distribution of certain controlled substances. We are cooperating with these investigations. We are unable to predict the outcome of any of these investigations. In total, as of September 30, 2023, we have $5.45 billion accrued for these matters, of which $420 million is included in other accrued liabilities and the remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets. Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits and none of these agreements is an admission of liability or wrongdoing. Please see below for additional description of these matters. States and Political Subdivisions In February 2022, we along with two other national distributors (collectively, the "Distributors") independently approved a settlement and settlement agreement (the "National Opioid Settlement Agreement") to settle the vast majority of opioid lawsuits and claims brought by states and political subdivisions. This National Opioid Settlement Agreement became effective on April 2, 2022. In addition to the Distributors, parties to the National Opioid Settlement Agreement include 48 states, the District of Columbia and 5 U.S. territories. Over 99 percent of political subdivisions in settling states (by population as calculated under the National Opioid Settlement Agreement) that had brought opioid-related suits against us have chosen to join the National Opioid Settlement Agreement or have had their claims addressed by state legislation (together with settling states and territories, the "Settling Governmental Entities"). As of July 2023, we have paid the Settling Governmental Entities approximately $1.2 billion, and will pay Settling Governmental Entities additional amounts up to $5.2 billion through 2038. The National Opioid Settlement Agreement also includes injunctive relief terms related to Distributors’ controlled substance anti-diversion programs. A monitor is overseeing compliance with these provisions until 2027. In addition, the Distributors are engaging a third-party vendor to act as a clearinghouse for data aggregation and reporting, which Distributors will fund for 10 years. As a result of the National Opioid Settlement Agreement, most lawsuits brought against us by states and other political subdivisions have been dismissed. We continue to engage in resolution discussions with certain nonparticipating political subdivisions, including the Attorney General for the State of Alabama, and intend to defend ourselves vigorously against all remaining lawsuits. A trial involving the Attorney General for the State of Alabama is scheduled to begin in February 2024. Other Settlements West Virginia subdivisions and Native American tribes were not a part of the National Opioid Settlement Agreement, and we had separate settlement negotiations with these groups. In July 2022, a judgment in favor of the Distributors was entered in bench trial before a federal judge in West Virginia in a case brought by Cabell County and City of Huntington. Plaintiffs have appealed this decision to the Fourth Circuit Court of Appeals. In July 2022, the Distributors reached an agreement to settle the opioid-related claims of the majority of the remaining West Virginia subdivisions. Under this agreement, we agreed to pay eligible West Virginia subdivisions up to approximately $124 million over an eleven-year period. This agreement became effective in October 2022 when all participating subdivisions dismissed their cases. In October 2022, we executed a final settlement agreement with the Native American Tribes, pursuant to which we will pay up to approximately $136 million over five years. In connection with this settlement, the court entered dismissals for the Native American tribes cases. Private Plaintiffs The National Opioid Settlement Agreement does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals alleging personal injury. Lawsuits brought by private plaintiffs that were pending as of October 31, 2023 were 394. Of these, 103 were purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. We are engaged in resolution discussions with certain private plaintiffs; however, we are vigorously defending ourselves in all these matters. A trial in a case involving 21 plaintiffs began in state court in Georgia in January 2023 and concluded in March 2023 with a verdict for the company and other defendants on all claims. In July 2023, the judge denied the plaintiffs' motion for a new trial. Plaintiffs have filed a notice of appeal and defendants have filed a notice of cross-appeal. A trial involving eight hospital plaintiffs that was scheduled to begin in Alabama in July 2023 was stayed pending appellate review of certain issues and has yet to be rescheduled. Insurance Litigation We are involved in ongoing legal proceedings with insurers related to their respective obligations to reimburse us for defense and indemnity costs in connection with the lawsuits described above. During fiscal year 2023, we received approximately $10 million in insurance recoveries related to these matters. Cordis IVC Filter Matters We have been named as a defendant in approximately 450 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 5,000 plaintiffs that allege personal injuries associated with the use of inferior vena cava ("IVC") filter products. These lawsuits sought a variety of remedies, including unspecified monetary damages. The divestiture of the Cordis business did not include product liability related to the IVC filters in the U.S. and Canada, which we retained. In April 2023, we executed a settlement agreement that, if certain conditions are satisfied, will resolve 4,375 claims for $275 million. This settlement agreement is subject to certain conditions, including certain opt-in thresholds. Between May and September 2023, we made settlement payments totaling $275 million into a qualified settlement fund, which will be disbursed to the plaintiffs if required conditions are satisfied. Since July 2021, we have also entered into other agreements to settle 2,798 product liability claims. While these settlements will resolve the vast majority of IVC filter product liability claims, they will not resolve all of them, and we intend to continue to vigorously defend ourselves in the remaining lawsuits. Additionally, in August 2021, the Attorney General for the State of New Mexico filed an action against certain IVC filter manufacturers, including us, alleging claims under New Mexico's Unfair Practices Act, Medicaid Fraud Act and Fraud Against Taxpayers Act. The allegations made are similar to those made in the product liability lawsuits. We intend to vigorously defend ourselves against these claims. We recognized income of $103 million during fiscal year 2023, primarily related to a reduction of the reserve for the estimated settlement and defense costs for these matters due to the execution of the settlements noted above. At September 30, 2023, we had a total of $304 million accrued for losses and legal defense costs, related to the IVC filter product liability lawsuits in our condensed consolidated balance sheets. Shareholder Securities Litigation In August 2019, the Louisiana Sheriffs' Pension & Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. In June 2020, the court appointed 1199 SEIU Health Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint was filed in September 2020. The amended complaint alleged that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") by making misrepresentations and omissions related to the acquisition and integration of the Cordis business and inventory and supply chain problems within the Cordis business and sought to recover unspecified damages and equitable relief for the alleged misstatements and omissions. The complaint also alleged that one of the individual defendants violated Section 20A of the Exchange Act because he sold shares of Cardinal Health stock during the time period. In February 2023, we reached an agreement in principle with the plaintiff to settle this matter for $109 million, with the settlement amount to be fully funded by our insurance carriers, subject to final approval by the court. In September 2023, the court entered an order granting final approval and dismissed the case. In fiscal year 2023, we had received approximately $9 million in insurance recoveries for costs incurred in connection with this matter. Other Civil Litigation Generic Pharmaceutical Pricing Antitrust Litigation In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. In May 2020, the court granted our motion to dismiss. In July 2022, the indirect purchasers filed an amended complaint and in August 2022, we filed a motion to dismiss the amended complaint. We are vigorously defending ourselves in this matter. Antitrust Litigation Proceeds We received and recognized income resulting from settlements of lawsuits in which we were a class member or plaintiff of $41 million, which were recognized in litigation (recoveries)/charges, net, during the three months ended September 30, 2023.

v3.23.3

Income Taxes	3 Months Ended
	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Income Tax Disclosure	7. Income Taxes Fluctuations in our benefit from income taxes as a percentage of our pre-tax earnings/(loss) (“effective tax rate”) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items. Effective Tax Rate During the three months ended September 30, 2023 and 2022, the effective tax rate was 122.5 percent and (0.7) percent, respectively. These tax rates reflect the impact of the tax effects of goodwill impairment charges recognized during the three months ended September 30, 2023 and 2022. Tax Effects of Goodwill Impairment Charge During the three months ended September 30, 2023, we recognized a $581 million pre-tax charge for goodwill impairment related to the Medical Unit. The net tax benefit related to this charge is $45 million for fiscal 2024. Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our impact from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur. The tax effect of the goodwill impairment charge during the three months ended September 30, 2023 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairments in prior fiscal years. The impact of the non-deductible goodwill increased the estimated annual effective tax rate for fiscal 2024. Applying the higher tax rate to pre-tax loss for three months ended September 30, 2023 resulted in recognizing an incremental interim tax benefit of approximately $99 million, which impacted the benefit from income taxes in the condensed consolidated statements of earnings during the three months ended September 30, 2023 and prepaid expenses and other assets in the condensed consolidated balance sheets at September 30, 2023. This interim tax benefit will reverse in future quarters of fiscal 2024. Unrecognized Tax Benefits We had $998 million and $1.0 billion of unrecognized tax benefits at September 30, 2023 and June 30, 2023, respectively. The September 30, 2023 and June 30, 2023 balances include $872 million and $873 million of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate. At September 30, 2023 and June 30, 2023, we had $68 million and $65 million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the benefit from income taxes in the condensed consolidated statements of earnings. These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of $51 million, exclusive of penalties and interest. Other Tax Matters We file income tax returns in the U.S. federal jurisdiction, various U.S. state and local jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year. We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), a subsidiary of Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $84 million and $82 million at September 30, 2023 and June 30, 2023 respectively, and is included in other assets in the condensed consolidated balance sheets.

v3.23.3

Fair Value Measurements	3 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	8. Fair Value Measurements Assets and Liabilities Measured on a Recurring Basis The following tables present the fair values for assets and (liabilities) measured on a recurring basis at: September 30, 2023 (in millions) Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 1,378  $ —  $ —  $ 1,378  Other investments (1) 93  —  —  93  Liabilities: Forward contracts (2) —  (104) —  (104) June 30, 2023 (in millions) Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 1,253  $ —  $ —  $ 1,253  Other investments (1) 101  —  —  101  Liabilities: Forward contracts (2) —  (73) —  (73) (1)The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices. (2) The fair value of interest rate swaps, foreign currency contracts and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets. Assets Measured on a Nonrecurring Basis As discussed further in Note 2, on July 10, 2023, we closed the transaction to contribute the Outcomes™ business to TDS, a portfolio company of BlackRock Long Term Private Capital and GTCR, in exchange for a 16 percent equity interest in the combined entity. We accounted for this investment initially at its fair value using Level 3 unobservable inputs under the discounted cash flow method. Accordingly, we recognized a $147 million equity method investment during the three months ended September 30, 2023.

v3.23.3

Financial Instruments	3 Months Ended
	Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments Disclosure	9. Financial Instruments We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements. Interest Rate Risk Management We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities on our fixed-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs. Currency Exchange Risk Management We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses. Commodity Price Risk Management We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases. Fair Value Hedges We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings. For the three months ended September 30, 2023 and 2022, there were no gains or losses recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt. During the three months ended September 30, 2023 and 2022, we entered into pay-floating interest rate swaps with total notional amounts of $100 million and $200 million, respectively. These swaps were designated as fair value hedges of our fixed rate debt and are included in deferred income taxes and other liabilities in our condensed consolidated balance sheets. Cash Flow Hedges We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings. Pre-tax gains recognized in other comprehensive income/(loss) were immaterial and $4 million for the three months ended September 30, 2023 and 2022, respectively. Gains recognized in accumulated other comprehensive loss and reclassified into earnings were immaterial for the three months ended September 30, 2023 and 2022. All gains and losses currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are immaterial. Net Investment Hedges We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments. During the three months ended September 30, 2023, we entered into ¥18 billion ($120 million) cross-currency swaps maturing in September 2025 and ¥18 billion ($120 million) cross-currency swaps maturing in June 2027. During the three months ended September 30, 2023, we terminated the ¥38 billion ($300 million) cross-currency swaps entered into in January 2023 and received a net settlement in cash of $28 million, recorded in proceeds from net investment hedge terminations in our condensed consolidated statements of cash flows. Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings. Pre-tax gains from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss were $11 million and $22 million for the three months ended September 30, 2023 and 2022, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of earnings for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $3 million and $4 million during the three months ended September 30, 2023 and 2022, respectively. Economic (Non-Designated) Hedges We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded an immaterial gain and a $6 million loss during the three months ended September 30, 2023 and 2022, respectively. The principal currencies managed through foreign currency contracts are the Chinese renminbi, Canadian dollar, Indian rupee, Euro and Thai baht. Fair Value of Financial Instruments The carrying amounts of cash and equivalents, trade receivables, accounts payable, and other accrued liabilities at September 30, 2023 and June 30, 2023 approximate fair value due to their short-term maturities. The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at: (in millions) September 30, 2023 June 30, 2023 Estimated fair value $ 4,270  $ 4,417  Carrying amount 4,678  4,701  The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.

v3.23.3

Shareholders' Equity	3 Months Ended
	Sep. 30, 2023
Equity [Abstract]
Shareholders' Equity	10. Shareholders' Deficit During the three months ended September 30, 2023, we entered into an accelerated share repurchase ("ASR") program to repurchase common shares for an aggregate purchase price of $500 million. We received an initial delivery of 4.4 million common shares using a reference price of $90.57. The program concluded on October 31, 2023 at a volume weighted average price per common share of $88.22 resulting in a final delivery of 1.3 million common shares. During June of fiscal year 2023, we entered into an ASR program to repurchase common shares for an aggregate purchase of $500 million. We received an initial delivery of 4.6 million common shares using a reference price of $87.18. The program concluded on August 16, 2023 at a volume weighted average price per common share of $91.15 resulting in a final delivery of 0.9 million common shares. During the three months ended September 30, 2022, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $1.0 billion. We received an initial delivery of 12.0 million common shares using a reference price of $66.74. The program concluded on December 23, 2022 at a volume weighted average price per common share of $73.36 resulting in a final delivery of 1.6 million common shares. We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes. Accumulated Other Comprehensive Loss The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total: (in millions) Foreign Currency Translation Adjustments Unrealized Gain/(Loss) on Derivatives, net of tax Accumulated Other Comprehensive Loss Balance at June 30, 2023 $ (137) $ (14) $ (151) Other comprehensive loss, before reclassifications (11) (1) (12) Amounts reclassified to earnings —  (2) (2) Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax expense of $3 million (11) (3) (14) Balance at September 30, 2023 $ (148) $ (17) $ (165) (in millions) Foreign Currency Translation Adjustments Unrealized Gain/(Loss) on Derivatives, net of tax Accumulated Other Comprehensive Loss Balance at June 30, 2022 $ (102) $ (12) $ (114) Other comprehensive loss, before reclassifications (58) (2) (60) Amounts reclassified to earnings —  (2) (2) Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax expense of $7 million (58) (4) (62) Balance at September 30, 2022 $ (160) $ (16) $ (176)

v3.23.3

Earnings Per Share Attributable to Cardinal Health, Inc.	3 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Earnings Per Share Attributable to Cardinal Health, Inc.	11. Earnings Per Share Attributable to Cardinal Health, Inc. The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.: Three Months Ended September 30, (in millions) 2023 2022 Weighted-average common shares–basic 249  271  Effect of dilutive securities: Employee stock options, restricted share units, and performance share units 1  2  Weighted-average common shares–diluted 250  273  The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive for the three months ended September 30, 2023 and 2022 were 1 million and 4 million, respectively.

v3.23.3

Segment Information	3 Months Ended
	Sep. 30, 2023
Segment Reporting [Abstract]
Segment Information	12. Segment Information Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities. Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; provides pharmacy management services to hospitals and operates a limited number of pharmacies, including pharmacies in community health centers; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; and repackages generic pharmaceuticals and over-the-counter healthcare products. Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of medical, surgical and laboratory products known as national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division. Revenue The following table presents revenue for each reportable segment, disaggregated revenue within our two reportable segments and Corporate: Three Months Ended September 30, (in millions) 2023 2022 Pharmaceutical and Specialty Pharmaceutical Distribution and Services (1) $ 50,682  $ 45,547  Nuclear and Precision Health Solutions 324  281  Pharmaceutical segment revenue 51,006  45,828  Medical Products and Distribution (2) 3,076  3,140  Cardinal Health at-Home Solutions 684  638  Medical segment revenue 3,760  3,778    Total segment revenue 54,766  49,606  Corporate (3) (3) (3) Total revenue $ 54,763  $ 49,603  (1)Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division. (2)Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division. (3)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments. The following table presents revenue by geographic area: Three Months Ended September 30, (in millions) 2023 2022 United States $ 53,557  $ 48,477  International 1,209  1,129    Total segment revenue 54,766  49,606  Corporate (1) (3) (3) Total revenue $ 54,763  $ 49,603  (1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments. Segment Profit We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&A") expenses. Segment SG&A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit. We do not allocate the following items to our segments: •last-in first-out, or ("LIFO"), inventory charges/(credits); •surgical gown recall costs/(income); •state opioid assessment related to prior fiscal years; in connection with the New York Opioid Stewardship Act as discussed further in Note 6; •shareholder cooperation agreement costs; •restructuring and employee severance; •amortization and other acquisition-related costs; •impairments and (gain)/loss on disposal of assets, net; in connection with goodwill impairment testing for the Medical Unit as discussed further in Note 4, we recognized pre-tax goodwill impairment charges of $581 million and $154 million during the three months ended September 2023 and 2022, respectively; •litigation (recoveries)/charges, net; •other (income)/expense, net; •interest expense, net; •loss on early extinguishment of debt; •(gain)/loss on sale of equity interest in naviHealth; or •provision for/(benefit from) income taxes In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $6 million for both the three months ended September 30, 2023 and 2022. The following table presents segment profit by reportable segment and Corporate: Three Months Ended September 30, (in millions) 2023 2022 Pharmaceutical $ 507  $ 431  Medical 71  (8) Total segment profit 578  423  Corporate (592) (286) Total operating earnings/(loss) $ (14) $ 137  The following table presents total assets for each reportable segment and Corporate at: (in millions) September 30, 2023 June 30, 2023 Pharmaceutical $ 28,968  $ 28,077  Medical 9,425  10,130  Corporate 5,317  5,210  Total assets $ 43,710  $ 43,417

v3.23.3

Share-Based Compensation	3 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation	13. Share-Based Compensation We maintain stock incentive plans (collectively, the “Plans”) for the benefit of certain of our officers, directors and employees. The following table provides total share-based compensation expense by type of award: Three Months Ended September 30, (in millions) 2023 2022 Restricted share unit expense $ 21  $ 17  Performance share unit expense 8  6  Total share-based compensation $ 29  $ 23  The total tax benefit related to share-based compensation was $4 million and $3 million for the three months ended September 30, 2023 and 2022, respectively. Restricted Share Units Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards. The following table summarizes all transactions related to restricted share units under the Plans: (in millions, except per share amounts) Restricted Share Units Weighted-Average Grant Date Fair Value per Share Nonvested at June 30, 2023 2.2  $ 57.37  Granted 0.8  90.40  Vested (1.0) 60.09  Canceled and forfeited —  —  Nonvested at September 30, 2023 2.0  $ 74.06  At September 30, 2023, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $116 million, which is expected to be recognized over a weighted-average period of two years. Performance Share Units Performance share units vest over a three-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 234 percent of the target award amount for both the fiscal 2022 and 2023 grants and zero to 240 percent of the target award for the fiscal 2024 grant. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards. The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts): (in millions, except per share amounts) Performance Share Units Weighted-Average Grant Date Fair Value per Share Nonvested at June 30, 2023 1.2  $ 82.17  Granted 0.5  94.66  Vested (0.4) 62.26  Canceled and forfeited —  —  Nonvested at September 30, 2023 1.3  $ 96.38  At September 30, 2023, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $64 million, which is expected to be recognized over a weighted-average period of two years if the performance goals are achieved.

v3.23.3

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Pay vs Performance Disclosure
Net earnings	$ 5	$ 110

v3.23.3

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2023 shares
Trading Arrangements, by Individual
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Deborah L. Weitzman [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	During the three months ended September 30, 2023, Deborah L. Weitzman, Chief Executive Officer, Pharmaceutical Segment, adopted a Rule 10b5-1 sales plan. Adopted on August 28, 2023, Ms. Weitzman's plan provides for the sale of up to 9,000 common shares and the exercise of vested stock options and the associated sale of up to 27,642 common shares through November 15, 2024. The plan was adopted during an open trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and our policies regarding insider transactions.
Name	Deborah L. Weitzman
Title	Chief Executive Officer, Pharmaceutical Segment
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	August 28, 2023
Arrangement Duration	445 days
Deborah L. Weitzman Trading Arrangement, Common Stock [Member] | Deborah L. Weitzman [Member]
Trading Arrangements, by Individual
Aggregate Available	9,000
Deborah L. Weitzman Trading Arrangement, Stock Options [Member] | Deborah L. Weitzman [Member]
Trading Arrangements, by Individual
Aggregate Available	27,642

v3.23.3

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively. References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (this "Form 10-Q") are to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise. Our fiscal year ends on June 30. References to fiscal 2024 and 2023 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2024 and June 30, 2023, respectively. Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. In addition, financial results presented for this fiscal 2024 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2024. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2023 (the "2023 Form 10-K").
Recent Financial Accounting Standards	Recently Issued Financial Accounting Standards Not Yet Adopted We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2023 Form 10-K. There were no accounting standards issued in fiscal 2024 that will have a material impact on our condensed consolidated financial statements. Recently Adopted Financial Accounting Standards There were no new material accounting standards adopted in the three months ended September 30, 2023.

v3.23.3

Restructuring and Employee Severance (Tables)	3 Months Ended
	Sep. 30, 2023
Restructuring Charges [Abstract]
Summary of Restructuring and Employee Severance	The following table summarizes restructuring and employee severance costs: Three Months Ended September 30, (in millions) 2023 2022 Employee-related costs $ 7  $ 19  Facility exit and other costs 18  10  Total restructuring and employee severance $ 25  $ 29
Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance	The following table summarizes activity related to liabilities associated with restructuring and employee severance: (in millions) Employee- Related Costs Facility Exit and Other Costs Total Balance at June 30, 2023 $ 44  $ 2  $ 46  Additions 6  4  10  Payments and other adjustments (15) (2) (17) Balance at September 30, 2023 $ 35  $ 4  $ 39

v3.23.3

Goodwill and Other Intangible Assets (Tables)	3 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill by Reportable Segment	The following table summarizes the changes in the carrying amount of goodwill by segment and in total: (in millions) Pharmaceutical Medical (1) Total Balance at June 30, 2023 $ 2,649  $ 1,960  $ 4,609  Foreign currency translation adjustments and other —  (3) (3) Goodwill impairment —  (581) (581) Balance at September 30, 2023 $ 2,649  $ 1,376  $ 4,025  (1)At September 30, 2023 and June 30, 2023, the Medical segment accumulated goodwill impairment loss was $5.3 billion and $4.7 billion, respectively.
Schedule of Definite and Indefinite-Lived Intangible Assets	The following tables summarize other intangible assets by class at: September 30, 2023 (in millions) Gross Intangible Accumulated Amortization Net Intangible Weighted- Average Remaining Amortization Period (Years) Indefinite-life intangibles: Trademarks and patents $ 12  $ —  $ 12  N/A Total indefinite-life intangibles 12  —  12  N/A Definite-life intangibles: Customer relationships 3,164  2,307  857  9 Trademarks, trade names and patents 546  387  159  8 Developed technology and other 1,021  642  379  8 Total definite-life intangibles 4,731  3,336  1,395  9 Total other intangible assets $ 4,743  $ 3,336  $ 1,407  N/A June 30, 2023 (in millions) Gross Intangible Accumulated Amortization Net Intangible Indefinite-life intangibles: Trademarks and patents $ 11  $ —  $ 11  Total indefinite-life intangibles 11  —  11  Definite-life intangibles: Customer relationships 3,174  2,274  900  Trademarks, trade names and patents 546  380  166  Developed technology and other 1,021  626  395  Total definite-life intangibles 4,741  3,280  1,461  Total other intangible assets $ 4,752  $ 3,280  $ 1,472

v3.23.3

Fair Value Measurements (Tables)	3 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value, Assets and Liabilities Measured on Recurring Basis	The following tables present the fair values for assets and (liabilities) measured on a recurring basis at: September 30, 2023 (in millions) Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 1,378  $ —  $ —  $ 1,378  Other investments (1) 93  —  —  93  Liabilities: Forward contracts (2) —  (104) —  (104) June 30, 2023 (in millions) Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 1,253  $ —  $ —  $ 1,253  Other investments (1) 101  —  —  101  Liabilities: Forward contracts (2) —  (73) —  (73) (1)The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices. (2) The fair value of interest rate swaps, foreign currency contracts and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.

v3.23.3

Financial Instruments (Tables)	3 Months Ended
	Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount	The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at: (in millions) September 30, 2023 June 30, 2023 Estimated fair value $ 4,270  $ 4,417  Carrying amount 4,678  4,701

v3.23.3

Shareholders' Equity (Tables)	3 Months Ended
	Sep. 30, 2023
Equity [Abstract]
Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total	Accumulated Other Comprehensive Loss The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total: (in millions) Foreign Currency Translation Adjustments Unrealized Gain/(Loss) on Derivatives, net of tax Accumulated Other Comprehensive Loss Balance at June 30, 2023 $ (137) $ (14) $ (151) Other comprehensive loss, before reclassifications (11) (1) (12) Amounts reclassified to earnings —  (2) (2) Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax expense of $3 million (11) (3) (14) Balance at September 30, 2023 $ (148) $ (17) $ (165) (in millions) Foreign Currency Translation Adjustments Unrealized Gain/(Loss) on Derivatives, net of tax Accumulated Other Comprehensive Loss Balance at June 30, 2022 $ (102) $ (12) $ (114) Other comprehensive loss, before reclassifications (58) (2) (60) Amounts reclassified to earnings —  (2) (2) Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax expense of $7 million (58) (4) (62) Balance at September 30, 2022 $ (160) $ (16) $ (176)

v3.23.3

Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)	3 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share	The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.: Three Months Ended September 30, (in millions) 2023 2022 Weighted-average common shares–basic 249  271  Effect of dilutive securities: Employee stock options, restricted share units, and performance share units 1  2  Weighted-average common shares–diluted 250  273

v3.23.3

Segment Information (Tables)	3 Months Ended
	Sep. 30, 2023
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue from External Customers by Geographic Areas [Table Text Block]	The following table presents revenue by geographic area: Three Months Ended September 30, (in millions) 2023 2022 United States $ 53,557  $ 48,477  International 1,209  1,129    Total segment revenue 54,766  49,606  Corporate (1) (3) (3) Total revenue $ 54,763  $ 49,603  (1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Revenue The following table presents revenue for each reportable segment, disaggregated revenue within our two reportable segments and Corporate: Three Months Ended September 30, (in millions) 2023 2022 Pharmaceutical and Specialty Pharmaceutical Distribution and Services (1) $ 50,682  $ 45,547  Nuclear and Precision Health Solutions 324  281  Pharmaceutical segment revenue 51,006  45,828  Medical Products and Distribution (2) 3,076  3,140  Cardinal Health at-Home Solutions 684  638  Medical segment revenue 3,760  3,778    Total segment revenue 54,766  49,606  Corporate (3) (3) (3) Total revenue $ 54,763  $ 49,603  (1)Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division. (2)Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division. (3)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Segment Profit by Reportable Segment	The following table presents segment profit by reportable segment and Corporate: Three Months Ended September 30, (in millions) 2023 2022 Pharmaceutical $ 507  $ 431  Medical 71  (8) Total segment profit 578  423  Corporate (592) (286) Total operating earnings/(loss) $ (14) $ 137
Assets by Reportable Segment	The following table presents total assets for each reportable segment and Corporate at: (in millions) September 30, 2023 June 30, 2023 Pharmaceutical $ 28,968  $ 28,077  Medical 9,425  10,130  Corporate 5,317  5,210  Total assets $ 43,710  $ 43,417

v3.23.3

Share-Based Compensation (Tables)	3 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Total Share-based Compensation Expense by Type of Award	The following table provides total share-based compensation expense by type of award: Three Months Ended September 30, (in millions) 2023 2022 Restricted share unit expense $ 21  $ 17  Performance share unit expense 8  6  Total share-based compensation $ 29  $ 23
Schedule of Transactions Related to Restricted Share Units Under the Plans	The following table summarizes all transactions related to restricted share units under the Plans: (in millions, except per share amounts) Restricted Share Units Weighted-Average Grant Date Fair Value per Share Nonvested at June 30, 2023 2.2  $ 57.37  Granted 0.8  90.40  Vested (1.0) 60.09  Canceled and forfeited —  —  Nonvested at September 30, 2023 2.0  $ 74.06
Schedule of Transactions Related to Performance Share Units Under the Plans	The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts): (in millions, except per share amounts) Performance Share Units Weighted-Average Grant Date Fair Value per Share Nonvested at June 30, 2023 1.2  $ 82.17  Granted 0.5  94.66  Vested (0.4) 62.26  Canceled and forfeited —  —  Nonvested at September 30, 2023 1.3  $ 96.38

v3.23.3

Divestitures (Details) $ in Millions	3 Months Ended
	Sep. 30, 2023 USD ($)
Long Lived Assets Held-for-sale [Line Items]
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]	Gain (Loss) on Sale of Assets and Asset Impairment Charges
Transaction Data System Investment [Member]
Long Lived Assets Held-for-sale [Line Items]
Equity Method Investments, Fair Value Disclosure	$ 147
Outcomes Divestiture
Long Lived Assets Held-for-sale [Line Items]
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal	$ 53

v3.23.3

Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Restructuring Charges [Abstract]
Employee-related costs	$ 7	$ 19
Facility Exit and Other Costs	18	10
Total restructuring and employee severance	$ 25	$ 29

v3.23.3

Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details) $ in Millions	3 Months Ended
	Sep. 30, 2023 USD ($)
Restructuring Reserve [Roll Forward]
Beginning Balance	$ 46
Additions	10
Payments and other adjustments	(17)
Ending Balance	39
Employee- Related Costs
Restructuring Reserve [Roll Forward]
Beginning Balance	44
Additions	6
Payments and other adjustments	(15)
Ending Balance	35
Facility Exit and Other Costs
Restructuring Reserve [Roll Forward]
Beginning Balance	2
Additions	4
Payments and other adjustments	(2)
Ending Balance	$ 4

v3.23.3

Restructuring and Employee Severance Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Restructuring Cost and Reserve [Line Items]
Severance Costs	$ 7	$ 19
Facility Exit and Other Costs	$ 18	$ 10

v3.23.3

Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2023
Goodwill [Roll Forward]
Beginning balance	$ 4,609
Foreign currency translation adjustments and other	(3)
Goodwill impairment	581
Ending balance	4,025
Pharmaceutical
Goodwill [Roll Forward]
Beginning balance	2,649
Foreign currency translation adjustments and other	0
Goodwill impairment	0
Ending balance	2,649
Medical
Goodwill [Roll Forward]
Beginning balance	1,960
Foreign currency translation adjustments and other	(3)
Goodwill impairment	581	$ 154
Ending balance	1,376
Goodwill, Impaired, Accumulated Impairment Loss	$ 5,300		$ 4,700

v3.23.3

Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) - USD ($) $ in Millions	Sep. 30, 2023	Jun. 30, 2023
Indefinite-lived Intangible Assets [Line Items]
Net Intangible	$ 12	$ 11
Finite-Lived Intangible Assets [Line Items]
Gross Intangible	4,731	4,741
Accumulated Amortization	3,336	3,280
Net Intangible	$ 1,395	1,461
Weighted- Average Remaining Amortization Period (Years)	9 years
Gross Intangible, Total other intangible assets	$ 4,743	4,752
Net Intangible, Total other intangible assets	1,407	1,472
Trademarks and patents
Indefinite-lived Intangible Assets [Line Items]
Net Intangible	12	11
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Intangible	3,164	3,174
Accumulated Amortization	2,307	2,274
Net Intangible	$ 857	900
Weighted- Average Remaining Amortization Period (Years)	9 years
Trademarks, trade names and patents
Finite-Lived Intangible Assets [Line Items]
Gross Intangible	$ 546	546
Accumulated Amortization	387	380
Net Intangible	$ 159	166
Weighted- Average Remaining Amortization Period (Years)	8 years
Developed technology and other
Finite-Lived Intangible Assets [Line Items]
Gross Intangible	$ 1,021	1,021
Accumulated Amortization	642	626
Net Intangible	$ 379	$ 395
Weighted- Average Remaining Amortization Period (Years)	8 years

v3.23.3

Goodwill and Other Intangible Assets Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 64		$ 71
Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year	190
Finite-Lived Intangible Asset, Expected Amortization, Year One	228
Finite-Lived Intangible Assets, Amortization Expense, Year Two	205
Finite-Lived Intangible Assets, Amortization Expense, Year Three	173
Finite-Lived Intangible Assets, Amortization Expense, Year Four	146
Goodwill [Line Items]
Goodwill impairment	581
Goodwill	$ 4,025	$ 4,609
Medical Unit [Member]
Goodwill [Line Items]
Discount Rate, Fair Value Input	11.00%	10.00%
Terminal Growth Rate, Fair Value Input	2.00%
Net Assets	$ 5,300
Goodwill	$ 141
Change in Discount Rate, Fair Value Input	1.00%
Medical
Goodwill [Line Items]
Goodwill impairment	$ 581		$ 154
Goodwill	$ 1,376	$ 1,960

v3.23.3

Long-Term Obligations and Other Short-Term Borrowings Narrative (Details) - USD ($) $ in Millions	Sep. 30, 2023	Jun. 30, 2023
Debt Instrument [Line Items]
Debt, Long-term and Short-term, Combined Amount	$ 4,700	$ 4,700
Accounts Payable	31,500	$ 29,800
Commercial Paper [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	2,000
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	2,000
Short Term Credit Facilities Member
Debt Instrument [Line Items]
Other Short-term Borrowings	0
Short Term Credit Facilities Member | Committed Receivables Sales Facility Program [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 1,000

v3.23.3

Commitments, Contingent Liabilities and Litigation Narrative (Details) $ in Thousands			3 Months Ended			5 Months Ended	12 Months Ended	27 Months Ended		176 Months Ended
	Oct. 31, 2023 lawsuit plaintiff	Apr. 30, 2023 lawsuit	Sep. 30, 2023 USD ($) states numberOfUSTerritories	Mar. 31, 2023 USD ($) plaintiff	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) states numberOfUSTerritories	Jun. 30, 2023 USD ($)	Oct. 31, 2023 lawsuit	Sep. 30, 2023 USD ($) states numberOfUSTerritories	Jun. 30, 2038 USD ($)	Oct. 31, 2022 USD ($)	Jul. 31, 2022 USD ($)	Apr. 30, 2018 USD ($)
Loss Contingencies [Line Items]
Gain (Loss) Related to Litigation Settlement			$ 41,000		$ (27,000)
Income from Settlements of Class Action Lawsuits			$ 41,000
Opioid Lawsuits [Member]
Loss Contingencies [Line Items]
Settling States | states			48			48			48
Settling U.S Territories | numberOfUSTerritories			5			5			5
Payments for Legal Settlements									$ 1,200,000
Insurance Recoveries							$ 10,000
Opioid Lawsuits [Member] | Subsequent Event
Loss Contingencies [Line Items]
Payments for Legal Settlements										$ 5,200,000
Product Liability Lawsuits [Member]
Loss Contingencies [Line Items]
Loss Contingency Accrual, Period Increase (Decrease)							103,000
Product Liability Lawsuits [Member] | IVC April 2023 Agreement
Loss Contingencies [Line Items]
Loss Contingency, Estimate of Possible Loss			$ 275,000			$ 275,000			275,000
Loss Contingency Accrual, Payments						275,000
New York Opioid Stewardship Act [Member]
Loss Contingencies [Line Items]
Aggregate Annual Assessment													$ 100,000
Loss Contingency Accrual, Period Increase (Decrease)							6,000
Loss Contingency Accrual							3,000
Shareholder Securities Litigation
Loss Contingencies [Line Items]
Insurance Recoveries							$ 9,000
Gain (Loss) Related to Litigation Settlement				$ 109,000
CVS Health
Loss Contingencies [Line Items]
Long-term Purchase Commitment, Period			10 years
Product Liability Lawsuits [Member] | Subsequent Event
Loss Contingencies [Line Items]
Loss Contingency, New Claims Filed, Number | lawsuit	450
Alameda County [Member] | Product Liability Lawsuits [Member] | Subsequent Event
Loss Contingencies [Line Items]
Number of plaintiffs | plaintiff	5,000
WEST VIRGINIA | Opioid Lawsuits [Member]
Loss Contingencies [Line Items]
Loss Contingency, Estimate of Possible Loss												$ 124,000
921150 American Indian and Alaska Native Tribal Governments | Opioid Lawsuits [Member]
Loss Contingencies [Line Items]
Loss Contingency, Estimate of Possible Loss											$ 136,000
Total Opioid Litigation [Member]
Loss Contingencies [Line Items]
litigation settlement liability recorded			$ 5,450,000			5,450,000			5,450,000
Estimated Litigation Liability, Current			420,000			420,000			420,000
Private Parties [Member] | Opioid Lawsuits [Member] | Subsequent Event
Loss Contingencies [Line Items]
Loss Contingency, Lawsuits, Number | lawsuit	394							394
Private Parties [Member] | GEORGIA | Opioid Lawsuits [Member]
Loss Contingencies [Line Items]
Number of plaintiffs | plaintiff				21
Class Action Lawsuits [Member] | Private Parties [Member] | Opioid Lawsuits [Member] | Subsequent Event
Loss Contingencies [Line Items]
Loss Contingency, Lawsuits, Number | lawsuit	103							103
Product Liability Lawsuits [Member] | IVC April 2023 Agreement
Loss Contingencies [Line Items]
Loss Contingency, Claims Settled, Number | lawsuit		4,375
Product Liability Lawsuits [Member] | Subsequent Event | Other Agreements
Loss Contingencies [Line Items]
Loss Contingency, Claims Settled, Number | lawsuit								2,798
Product Liability Lawsuits [Member] | Minimum
Loss Contingencies [Line Items]
Loss Contingency Accrual			$ 304,000			$ 304,000			$ 304,000

v3.23.3

Income Taxes Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2024	Jun. 30, 2024	Jun. 30, 2023
Income Taxes
Benefit from income taxes	$ (32)	$ (1)
Effective Income Tax Rate Reconciliation, Percent	122.50%	(0.70%)
Unrecognized tax benefits	$ 998				$ 1,000
Unrecognized tax benefits that would impact effective tax rate	872				873
Unrecognized tax benefits, interest and penalties accrued	68				65
Goodwill impairment	581
Medical Unit Goodwill Impairment [Member] | Subsequent Event
Income Taxes
Benefit from income taxes			$ 99
Medical
Income Taxes
Goodwill impairment	581	$ 154
Forecast [Member] | Medical
Income Taxes
Benefit from income taxes				$ (45)
Minimum
Income Taxes
Estimated range of decrease in unrecognized tax benefits within the next 12 months	0
Maximum
Income Taxes
Estimated range of decrease in unrecognized tax benefits within the next 12 months	$ 51
Federal | Minimum
Income Taxes
Open Tax Year	2015
CareFusion [Member]
Income Taxes
Indemnification receivable	$ 84				$ 82

v3.23.3

Fair Value Measurements Narrative (Details) - USD ($) $ in Millions	Sep. 30, 2023	Jun. 30, 2023
Transaction Data System Investment [Member]
Assets:
Equity Method Investments, Fair Value Disclosure	$ 147
Recurring
Assets:
Other investments	93	$ 101
Forward Contract	(104)	(73)
Recurring | Level 1
Assets:
Cash equivalents	1,378	1,253
Other investments	93	101
Forward Contract	0	0
Recurring | Level 2
Assets:
Cash equivalents	0	0
Other investments	0	0
Forward Contract	(104)	(73)
Recurring | Level 3
Assets:
Cash equivalents	0	0
Other investments	0	0
Forward Contract	0	0
Recurring | Fair Value, Inputs, Level 1, 2 and 3
Assets:
Cash equivalents	$ 1,378	$ 1,253
Fair Value, Nonrecurring | Transaction Data System Investment [Member]
Assets:
Equity Method Investment, Ownership Percentage	16.00%
Equity Method Investments, Fair Value Disclosure	$ 147

v3.23.3

Financial Instruments Narrative (Details) ¥ in Millions, $ in Millions	3 Months Ended
	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 JPY (¥)
Derivative [Line Items]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	$ 0
Proceeds from Hedge, Investing Activities	28	$ 0
January 2023
Derivative [Line Items]
Proceeds from Hedge, Investing Activities	28
Foreign Exchange Contract [Member]
Derivative [Line Items]
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax	11	22
Interest Income (Expense), Nonoperating, Net	3	4
Cash Flow Hedging [Member]
Derivative [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax		4
Designated as Hedging Instrument | Fair Value Hedging | Interest Rate Swap
Derivative [Line Items]
Notional Amount	100	200
Designated as Hedging Instrument | Net Investment Hedging | Currency Swap [Member] | January 2023
Derivative [Line Items]
Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount	300		¥ 38,000
Designated as Hedging Instrument | Net Investment Hedging | Currency Swap [Member] | September 2025
Derivative [Line Items]
Derivative Asset, Notional Amount	120		18,000
Designated as Hedging Instrument | Net Investment Hedging | Currency Swap [Member] | June 2027
Derivative [Line Items]
Derivative Asset, Notional Amount	$ 120		¥ 18,000
Other Nonoperating Income (Expense) | Not Designated as Hedging Instrument | Foreign Exchange Contract [Member]
Derivative [Line Items]
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net		$ 6

v3.23.3

Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details) - USD ($) $ in Millions	Sep. 30, 2023	Jun. 30, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Amount of Long-Term and other Short-Term Borrowings	$ 4,678	$ 4,701
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Estimated fair value	$ 4,270	$ 4,417

v3.23.3

Shareholders' Equity Narrative (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions				1 Months Ended	3 Months Ended			4 Months Ended	6 Months Ended
	Oct. 31, 2023	Aug. 18, 2023	Dec. 23, 2022	Jun. 30, 2023	Sep. 30, 2023	Aug. 18, 2023	Sep. 30, 2022	Oct. 31, 2023	Dec. 23, 2022
Class of Stock [Line Items]
Share repurchase program activity					$ 500		$ 1,000
$1 billion share repurchase program
Class of Stock [Line Items]
Share repurchase program activity							$ 1,000
$500 million share repurchase program
Class of Stock [Line Items]
Share repurchase program activity				$ 500	$ 500
Treasury Shares
Class of Stock [Line Items]
Treasury shares acquired (using cost method), shares					5.0		12.0
Treasury Shares | $500 million share repurchase program
Class of Stock [Line Items]
Treasury shares acquired (using cost method), shares		0.9
Treasury shares acquired, average price per share (in usd per share)				$ 87.18		$ 91.15
Treasury Shares | $1 billion share repurchase program
Class of Stock [Line Items]
Treasury shares acquired (using cost method), shares							12.0
Treasury shares acquired, average price per share (in usd per share)							$ 66.74
Treasury Shares | $500 million share repurchase program
Class of Stock [Line Items]
Treasury shares acquired (using cost method), shares			1.6	4.6	4.4
Treasury shares acquired, average price per share (in usd per share)					$ 90.57				$ 73.36
Subsequent Event | Treasury Shares | $500 million share repurchase program
Class of Stock [Line Items]
Treasury shares acquired (using cost method), shares	1.3
Treasury shares acquired, average price per share (in usd per share)								$ 88.22

v3.23.3

Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
AOCI, Net of Tax [Roll Forward]
Balance at beginning of period	$ (2,851)	$ (706)
Total other comprehensive loss, net of tax	(14)	(62)
Other Comprehensive Income (Loss), Tax	3	7
Balance at end of period	(3,490)	(1,780)
Foreign Currency Translation Adjustments
AOCI, Net of Tax [Roll Forward]
Balance at beginning of period	(137)	(102)
Other comprehensive loss, before reclassifications	(11)	(58)
Amounts reclassified to earnings	0	0
Total other comprehensive loss, net of tax	(11)	(58)
Balance at end of period	(148)	(160)
Unrealized Gain/(Loss) on Derivatives, net of tax
AOCI, Net of Tax [Roll Forward]
Balance at beginning of period	(14)	(12)
Other comprehensive loss, before reclassifications	(1)	(2)
Amounts reclassified to earnings	(2)	(2)
Total other comprehensive loss, net of tax	(3)	(4)
Balance at end of period	(17)	(16)
Accumulated Other Comprehensive Loss
AOCI, Net of Tax [Roll Forward]
Balance at beginning of period	(151)	(114)
Total other comprehensive loss, net of tax	(14)	(62)
Balance at end of period	(165)	(176)
Accumulated Other Comprehensive Loss
AOCI, Net of Tax [Roll Forward]
Balance at beginning of period	(151)	(114)
Other comprehensive loss, before reclassifications	(12)	(60)
Amounts reclassified to earnings	(2)	(2)
Balance at end of period	$ (165)	$ (176)

v3.23.3

Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) - shares shares in Millions	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Earnings Per Share [Abstract]
Weighted-average common shares–basic (in shares)	249	271
Effect of dilutive securities:
Weighted Average Number Diluted Shares Outstanding Adjustment	1	2
Weighted-average common shares–diluted (in shares)	250	273

v3.23.3

Earnings Per Share Attributable to Cardinal Health, Inc. Narrative (Details) - shares shares in Millions	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Earnings Per Share [Abstract]
Weighted Average Number Diluted Shares Outstanding Adjustment	1	4

v3.23.3

Segment Information Narrative (Details) $ in Millions	3 Months Ended
	Sep. 30, 2023 USD ($) segment	Sep. 30, 2022 USD ($)
Gain (Loss) Related to Litigation Settlement	$ 41	$ (27)
Goodwill impairment	$ 581
Number of operating segments | segment	2
Number of Reportable Segments | segment	2
Project Costs On Investment And Other Spending	$ 6
Total Opioid Litigation [Member]
Estimated Litigation Liability	$ 5,450

v3.23.3

Segment Information (Revenue by Reportable Segment) (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Segment Reporting Information [Line Items]
Total revenue	$ 54,763	$ 49,603
Operating Segments
Segment Reporting Information [Line Items]
Total revenue	54,766	49,606
Operating Segments | Pharmaceutical
Segment Reporting Information [Line Items]
Total revenue	51,006	45,828
Operating Segments | Medical
Segment Reporting Information [Line Items]
Total revenue	3,760	3,778
Corporate
Segment Reporting Information [Line Items]
Total revenue	(3)	(3)
Nuclear Precision Health Services [Member] | Operating Segments | Pharmaceutical
Segment Reporting Information [Line Items]
Total revenue	324	281
Pharmaceutical Distribution and Specialty [Member] | Operating Segments | Pharmaceutical
Segment Reporting Information [Line Items]
Total revenue	50,682	45,547
Medical distribution and products [Member] | Operating Segments | Medical
Segment Reporting Information [Line Items]
Total revenue	3,076	3,140
Cardinal Health At Home Solutions [Member] | Operating Segments | Medical
Segment Reporting Information [Line Items]
Total revenue	$ 684	$ 638

v3.23.3

Segment Information (Segment Profit by Reportable Segment) (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total operating earnings	$ (14)	$ 137
Operating Segments
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total operating earnings	578	423
Operating Segments | Pharmaceutical
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total operating earnings	507	431
Operating Segments | Medical
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total operating earnings	71	(8)
Corporate
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total operating earnings	$ (592)	$ (286)

v3.23.3

Segment Information (Assets by Reportable Segment) (Details) - USD ($) $ in Millions	Sep. 30, 2023	Jun. 30, 2023
Segment Reporting Information [Line Items]
Total assets	$ 43,710	$ 43,417
Operating Segments | Pharmaceutical
Segment Reporting Information [Line Items]
Total assets	28,968	28,077
Operating Segments | Medical
Segment Reporting Information [Line Items]
Total assets	9,425	10,130
Corporate
Segment Reporting Information [Line Items]
Total assets	$ 5,317	$ 5,210

v3.23.3

Segment Information Disaggregated Revenue Within Reportable Segments (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue	$ 54,763	$ 49,603
Operating Segments
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue	54,766	49,606
Operating Segments | Pharmaceutical
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue	51,006	45,828
Operating Segments | Pharmaceutical | Nuclear Precision Health Services [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue	324	281
Operating Segments | Pharmaceutical | Pharmaceutical Distribution and Specialty [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue	50,682	45,547
Operating Segments | Medical
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue	3,760	3,778
Operating Segments | Medical | Medical distribution and products [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue	3,076	3,140
Corporate
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue	$ (3)	$ (3)

v3.23.3

Segment Information Revenue by Geographical Segments (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Segment Revenue by Geographic [Line Items]
Revenue	$ 54,763	$ 49,603
UNITED STATES
Segment Revenue by Geographic [Line Items]
Revenue	53,557	48,477
Non-US [Member]
Segment Revenue by Geographic [Line Items]
Revenue	1,209	1,129
Operating Segments
Segment Revenue by Geographic [Line Items]
Revenue	54,766	49,606
Corporate
Segment Revenue by Geographic [Line Items]
Revenue	$ (3)	$ (3)

v3.23.3

Share-Based Compensation Narrative (Details) $ in Millions	3 Months Ended		12 Months Ended
	Sep. 30, 2023 USD ($) Reportable_Segments	Sep. 30, 2022 USD ($)	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Tax benefit related to share-based compensation	$ 4	$ 3
Restricted Share Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)	3 years
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 116
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition	2 years
Performance Share Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 64
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition	2 years
Vesting Period in years for Shares | Reportable_Segments	3
Performance Share Units | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Target performance goal (as a percent)			0.00%	0.00%
Performance Share Units | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Target performance goal (as a percent)			234.00%	234.00%

v3.23.3

Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation	$ 29	$ 23
Restricted Share Unit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation	21	17
Performance Share Unit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation	$ 8	$ 6

v3.23.3

Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) - Restricted Share Units shares in Millions	3 Months Ended
	Sep. 30, 2023 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition	2 years
Restricted Share Units
Nonvested at beginning of period (in shares) | shares	2.2
Granted (in shares) | shares	0.8
Vested (in shares) | shares	(1.0)
Canceled and forfeited (in shares) | shares	0.0
Nonvested at end of period (in shares) | shares	2.0
Weighted-Average Grant Date Fair Value per Share
Nonvested at beginning of period (in usd per share) | $ / shares	$ 57.37
Granted (in usd per share) | $ / shares	90.40
Vested (in usd per share) | $ / shares	60.09
Canceled and forfeited (in usd per share) | $ / shares	0
Nonvested at end of period (in usd per share) | $ / shares	$ 74.06

v3.23.3

Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) - Performance Share Units $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Sep. 30, 2023 USD ($) $ / shares shares
Performance Share Units
Nonvested at beginning of period (in shares) | shares	1.2
Granted (in shares) | shares	0.5
Vested (in shares) | shares	(0.4)
Canceled and forfeited (in shares) | shares	0.0
Nonvested at end of period (in shares) | shares	1.3
Weighted-Average Grant Date Fair Value per Share
Nonvested at beginning of period (in usd per share) | $ / shares	$ 82.17
Granted (in usd per share) | $ / shares	94.66
Vested (in usd per share) | $ / shares	62.26
Canceled and forfeited (in usd per share) | $ / shares	0
Nonvested at end of period (in usd per share) | $ / shares	$ 96.38
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $	$ 64
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition	2 years

---